Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609601 | 0.90 | ACHE (0.48) | ACHECYP3A4MEN1KMT2ATSHR | |
| Hydrochloric Acid SCHEMBL8708412 | 0.88 | ACHE (0.47) | ACHECYP3A4MEN1KMT2ATSHR | |
| SCHEMBL1858912 | 0.86 | CHRNB2 (0.41) | ACHECYP3A4MEN1KMT2ATSHR | |
| SCHEMBL10258004 | 0.86 | CHRNB2 (0.41) | ACHECYP3A4MEN1KMT2ATSHR | |
| SCHEMBL10257201 | 0.86 | CHRNB2 (0.41) | ACHECYP3A4MEN1KMT2ATSHR | |
| SCHEMBL23612449 | 0.79 | KARS1 (0.40) | CYP3A4MEN1KMT2ATSHRPDK1 | |
| SCHEMBL5851744 | 0.78 | ACHE (0.48) | ACHE | |
| SCHEMBL10257512 | 0.76 | CHRNB2 (0.39) | ACHECYP3A4MEN1KMT2ATSHR | |
| SCHEMBL10257602 | 0.76 | CHRNB2 (0.39) | ACHECYP3A4MEN1KMT2ATSHR | |
| SCHEMBL332173 | 0.76 | ACHE (0.37) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11179473-B2 | Nectin-4 antibody conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210275683-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | ARARIS BIOTECH AG (CH) | 2021-09-09 | — | — | US | disclosed |
| US-20210154188-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210077632-A1 | Formulations of Benzazepine Conjugates and Uses Thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | ARS Pharmaceuticals, Inc. | 2020-01-30 | — | — | US | disclosed |
| US-10442790-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| WO-2019195278-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-10428045-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077632-A1 | Formulations of Benzazepine Conjugates and Uses Thereof | BDNF, FURIN, VGF | ACHE 222/4885CYP3A4 469/4885MEN1 1163/4885 |
| US-20210275683-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | NECTIN4, SIGLEC7, CD2 | ACHE 3439/4885CYP3A4 3809/4885MEN1 747/4885 |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | ACHE 4860/4885CYP3A4 4082/4885MEN1 3890/4885 |
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | ACHE 2683/4885CYP3A4 2534/4885MEN1 2662/4885 |
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | ACHE 2683/4885CYP3A4 2534/4885MEN1 2662/4885 |
| US-10442790-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | ACHE 2683/4885CYP3A4 2534/4885MEN1 2662/4885 |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | TGFBR2, ASGR1, TGFBR1 | ACHE 4690/4885CYP3A4 3978/4885MEN1 2700/4885 |
| US-11179473-B2 | Nectin-4 antibody conjugates and uses thereof | NECTIN4, SIGLEC7, CD2 | ACHE 3439/4885CYP3A4 3809/4885MEN1 747/4885 |
| US-10428045-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | ACHE 2683/4885CYP3A4 2534/4885MEN1 2662/4885 |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | ACHE 2683/4885CYP3A4 2534/4885MEN1 2662/4885 |
| US-20210154188-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ALKBH3 | ACHE 2146/4885CYP3A4 2686/4885MEN1 2002/4885 |
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | ACHE 2683/4885CYP3A4 2534/4885MEN1 2662/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | ACHE 4876/4885CYP3A4 4056/4885MEN1 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.